The agreement may help Alvotech capitalize on a recent policy shift by CVS that has driven major market share declines for AbbVie’s blockbuster drug.

The new label for Alecensa makes it the first targeted treatment available after surgery for people with ALK-positive lung tumors, who are at high risk for brain metastases.

It’s “early innings” in the obesity drug race, said Metsera CEO Clive Meanwell, whose company acquired a portfolio of medicines it aims to test in combination.

Analysts had low expectations for Cerevel’s drug tavapadon, which was something of an afterthought in AbbVie’s proposed buyout of the biotech.

Through this partnership, ProPharma will leverage best practices to efficiently build and maintain study databases of any size, length, or complexity, ensuring optimal management of timelines, ...

The start of a so-called rolling review formally begins an FDA evaluation of a closely watched drug that’s important to the biotech’s future, but faces questions about its sales potential.

Before the war, Ukraine was becoming pharma’s “darling” of clinical trials, said Andreas Muehler, chief medical officer of Immunic Therapeutics, a U.S. and German biotechnology company currently ...

The companies plan to launch their copycat version of the blockbuster immune disease drug early next year, per a legal settlement with J&J.

“This exciting breakthrough with use of the first biomimetic digital twins comes at a very exciting time for us, not only in ...

Tecvayli sales, which J&J broke out for the first time, surpassed Wall Street forecasts and offset underperformance from Carvykti, which J&J attributed to the "phasing and timing of orders." ...

Joel Marcus, the longtime head of Alexandria Real Estate Equities, sees few near-term challengers to the established biotech hubs of Boston, San Diego and San Francisco.

Shares of the biotech rose 25% after a large trial found adding its drug Caplyta onto antidepressant therapy significantly helped people with major depression.